The concern of generic competition has consistently loomed around copyright’s iconic drug, Viagra, triggering questions about the prospects of similar pharmaceutical portfolios. While first times saw significant gains, the patent end has created the way for discounted alternatives, possibly reducing profitability and creating a significant danger